Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.67 |
| ▸ | HTR2C | P28335 | 6/20 | 0.67 |
| ▸ | HTR2B | P41595 | 6/20 | 0.67 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1841583 | 1.00 | HTR2A (0.67) | HTR2AHTR2CHTR2BCHRNB4CHRNA3 | |
| SCHEMBL12020671 | 1.00 | HTR2A (0.67) | HTR2AHTR2CHTR2BCHRNB4CHRNA3 | |
| SCHEMBL12020812 | 1.00 | HTR2A (0.67) | HTR2AHTR2CHTR2BCHRNB4CHRNA3 | |
| SCHEMBL12020665 | 1.00 | HTR2A (0.67) | HTR2AHTR2CHTR2BCHRNB4CHRNA3 | |
| SCHEMBL730351 | 0.84 | HTR2A (0.50) | HTR2AHTR2CHTR2BCHRNB4CHRNA3 | |
| Faxeladol SCHEMBL616828 | 0.80 | SLC6A4 (0.50) | HTR2AHTR2CHTR2BSLC6A4 | |
| Faxeladol SCHEMBL149508 | 0.80 | SLC6A4 (0.50) | HTR2AHTR2CHTR2BSLC6A4 | |
| Faxeladol SCHEMBL354208 | 0.80 | SLC6A4 (0.50) | HTR2AHTR2CHTR2BSLC6A4 | |
| SCHEMBL1841310 | 0.80 | SLC6A4 (0.50) | HTR2AHTR2CHTR2BCHRNB4CHRNA3 | |
| Faxeladol SCHEMBL149507 | 0.80 | SLC6A4 (0.50) | HTR2AHTR2CHTR2BSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130296414-A1 | 1-Phenyl-2-Dimethylaminomethyl Cyclohexane Compounds And Therapies For Depressive Symptoms, Pain and Incontinence | GRUENENTHAL GMBH (DE) | 2013-11-07 | — | — | US | claimed |
| US-20110263699-A1 | 1-Phenyl-2-DimethylaminomethylCyclohexane Compounds and Therapies for Depressive Symptoms, Pain and Incontinence | GRUENENTHAL GMBH (DE) | 2011-10-27 | — | — | US | claimed |
| EP-1686984-B1 | USE OF C-(2-PHENYL-CYCLOHEXYL)-METHYLAMINE COMPOUNDS FOR THE TREATMENT OF ANXIETY DISORDERS | GRUENENTHAL GMBH (DE) | 2011-05-18 | — | — | EP | claimed |
| EP-1530462-B1 | 1-PHENYL-2-DIMETHYLAMINOMETHYL CYCLOHEXANE COMPOUNDS USED FOR THE THERAPY OF DEPRESSIVE SYMPTOMS, PAIN, AND INCONTINENCE | GRUENENTHAL GMBH (DE) | 2010-12-15 | — | — | EP | claimed |
| US-20100249225-A1 | C-(2-Phenyl-Cyclohexyl)-Methylamine Compounds for the Treatment of Anxiety Disorders | GRUENENTHAL GMBH (DE) | 2010-09-30 | — | — | US | claimed |
| US-20100004341-A1 | C-(2-Phenyl-Cyclohexyl)-Methylamine Compounds for Therapy of Fibromyalgia | GRUENENTHAL GMBH (DE) | 2010-01-07 | — | — | US | claimed |
| EP-1970060-A2 | Use of C-(2-Phenyl-cyclohexyl)-methylamine compounds for fibromyalgia therapy | Grünenthal GmbH (DE) | 2008-09-17 | — | — | EP | claimed |
| US-20060258741-A1 | C-(2-phenyl-cyclohexyl)-methylamine compounds for the treatment of anxiety disorders | GRUENENTHAL GMBH | 2006-11-16 | — | — | US | claimed |
| EP-1686984-A1 | USE OF C-(2-PHENYL-CYCLOHEXYL)-METHYLAMINE COMPOUNDS FOR THE TREATMENT OF ANXIETY DISORDERS | Grünenthal GmbH (DE) | 2006-08-09 | — | — | EP | claimed |
| CN-1697651-A | 1-phenyl-2-dimethylaminomethyl cyclohexane compounds and therapies for depressive symptoms, pain and incontinence | KRAUSE GEORG (DE) | 2005-11-16 | — | — | CN | claimed |
| US-20050182131-A1 | 1-Phenyl-2-dimethylaminomethyl cyclohexane compounds and therapies for depressive symptoms, pain and incontinence | GRUENENTHAL GMBH (DE) | 2005-08-18 | — | — | US | claimed |
| WO-2005051375-A1 | USE OF C-(2-PHENYL-CYCLOHEXYL)-METHYLAMINE COMPOUNDS FOR THE TREATMENT OF ANXIETY DISORDERS | Grünenthal GmbH (DE) | 2005-06-09 | — | — | WO | claimed |
| EP-1530462-A1 | 1-PHENYL-2-DIMETHYLAMINOMETHYL CYCLOHEXANE COMPOUNDS USED FOR THE THERAPY OF DEPRESSIVE SYMPTOMS, PAIN, AND INCONTINENCE | Grünenthal GmbH (DE) | 2005-05-18 | — | — | EP | claimed |
| WO-2004009067-A1 | 1-PHENYL-2-DIMETHYLAMINOMETHYL CYCLOHEXANE COMPOUNDS USED FOR THE THERAPY OF DEPRESSIVE SYMPTOMS, PAIN, AND INCONTINENCE | Grünenthal GmbH (DE) | 2004-01-29 | — | — | WO | claimed |
| US-9850198-B2 | Process for preparing substituted 3-(1-amino-2-methylpentane-3-yl)phenyl compounds | GRUENENTHAL GMBH (DE) | 2017-12-26 | — | — | US | disclosed |
| EP-2792668-B1 | Process for the preparation of substituted 3-(1-amino-2-methyl-pentane-3-yl)phenyl compounds | GRUENENTHAL GMBH (DE) | 2017-05-31 | — | — | EP | disclosed |
| CN-104725246-B | Process For Preparing Substituted 3-(1-amino-2-methylpentane-3-yl)phenyl Compounds | 格吕伦塔尔有限公司 | 2017-05-03 | — | — | CN | disclosed |
| WO-2005051375-A1 | USE OF C-(2-PHENYL-CYCLOHEXYL)-METHYLAMINE COMPOUNDS FOR THE TREATMENT OF ANXIETY DISORDERS | Grünenthal GmbH (DE) | 2005-06-09 | — | — | WO | disclosed |
| EP-1530462-A1 | 1-PHENYL-2-DIMETHYLAMINOMETHYL CYCLOHEXANE COMPOUNDS USED FOR THE THERAPY OF DEPRESSIVE SYMPTOMS, PAIN, AND INCONTINENCE | Grünenthal GmbH (DE) | 2005-05-18 | — | — | EP | disclosed |
| WO-2004009067-A1 | 1-PHENYL-2-DIMETHYLAMINOMETHYL CYCLOHEXANE COMPOUNDS USED FOR THE THERAPY OF DEPRESSIVE SYMPTOMS, PAIN, AND INCONTINENCE | Grünenthal GmbH (DE) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258741-A1 | C-(2-phenyl-cyclohexyl)-methylamine compounds for the treatment of anxiety disorders | PNMT, HTR2C, HTR2A | HTR2A 3/4885HTR2C 2/4885HTR2B 14/4885 |
| US-20100004341-A1 | C-(2-Phenyl-Cyclohexyl)-Methylamine Compounds for Therapy of Fibromyalgia | PNMT, HNMT, GNMT | HTR2A 13/4885HTR2C 11/4885HTR2B 46/4885 |
| US-20050182131-A1 | 1-Phenyl-2-dimethylaminomethyl cyclohexane compounds and therapies for depressive symptoms, pain and incontinence | PNMT, HNMT, BHMT2 | HTR2A 18/4885HTR2C 10/4885HTR2B 51/4885 |
| US-20130296414-A1 | 1-Phenyl-2-Dimethylaminomethyl Cyclohexane Compounds And Therapies For Depressive Symptoms, Pain and Incontinence | PNMT, HNMT, OPRM1 | HTR2A 22/4885HTR2C 12/4885HTR2B 87/4885 |
| US-20100249225-A1 | C-(2-Phenyl-Cyclohexyl)-Methylamine Compounds for the Treatment of Anxiety Disorders | PNMT, HTR2C, HTR2A | HTR2A 3/4885HTR2C 2/4885HTR2B 14/4885 |
| US-20110263699-A1 | 1-Phenyl-2-DimethylaminomethylCyclohexane Compounds and Therapies for Depressive Symptoms, Pain and Incontinence | PNMT, HNMT, OPRM1 | HTR2A 17/4885HTR2C 5/4885HTR2B 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.